Navigation Links
Idenix Pharmaceuticals Prices Public Offering of Common Stock
Date:4/8/2011

CAMBRIDGE, Mass., April 8, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix. The offering is expected to close on April 13, 2011, subject to customary closing conditions.

J.P. Morgan Securities LLC is acting as sole book-running manager and underwriter for the offering. Idenix has granted the underwriter a 30-day option to purchase up to an additional 2,746,500 shares to cover over-allotments, if any.

The shares will be issued pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. Idenix will also file with the Securities and Exchange Commission a prospectus supplement with respect to the offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Idenix, nor shall there be any offer or sale of securities in any state or jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying prospectus may be obtained, when available, from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's curre
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
5. Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2010 Financial Results
6. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
7. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
11. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... -- Boston Biomedical, an industry leader in the development of ... pathways, will present clinical data today on the investigational ... the 2015 American Society of Clinical Oncology (ASCO) annual ... Data presented at ASCO highlight the potential of BBI608 ... to inhibition of the critical genes for maintaining cancer ...
(Date:6/1/2015)... /CNW Telbec/ -  Ergoresearch Ltd (TSXV: ERG) – based ... « Équilibre, orthèses et biomécanique» banner  – announces its ... All dollar amounts in the present release are in Canadian ... fiscal year 2015 ended this past March 31, 2015 totaled ... for the quarter ended March 31, 2014. This decrease can ...
(Date:6/1/2015)... 1, 2015 /PRNewswire/ - Merus Labs International Inc. ("Merus" ... ) is pleased to announce today that the ... the over-allotment option to purchase 1,000,550 common shares ... C$3.05 per Share granted to the Underwriters in ... which closed on April 30, 2015.  The Company ...
Breaking Medicine Technology:Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 4Merus Labs International Inc. Announces Closing of Exercise of Over-Allotment Option 2
... 2011 S*BIO Pte Ltd today announced that its ... (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive ... in vitro data on SB2343 were presented ... on Targeting PI3K/mTOR Signaling in Cancer held in San ...
... Feb. 28, 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: ... Appeal of the European Patent Office (EPO) has cancelled its ... decision upholding PDL,s  European Patent No. 0 451 216B (the ... the termination of the opposition appeal proceeding is that the ...
Cached Medicine Technology:S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 2S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 3PDL BioPharma Announces European Patent Office Determination of Validity of PDL's European Patent is Final 2
(Date:6/1/2015)... June 01, 2015 On May 14, ... center hosted the Cherry Creek Chamber of Commerce ... clinic. Urgent care centers typically do not offer primary ... AFC/Doctors Express Cherry Creek Urgent Care staff to schedule ... , From 5:30 to 7:30 p.m. the center hosted ...
(Date:6/1/2015)... "This milestone opens the doors to institutional ... to buy and sell shares of our Company. ... make recommendations to clients as they so choose. It ... shares of our Company,” said Kris Finstad, Content Checked’s ... OTCQB provides our investors greater confidence in the information ...
(Date:6/1/2015)... York, NY (PRWEB) June 01, 2015 ... by patients requesting celebrity features. Much like one would ... favorite stars’ noses, eyes, cheeks, chin and more to ... photo filtering apps like FaceTune are ushering in a ... Top Manhattan facial plastic surgeon, Sam Rizk, MD, FACS ...
(Date:6/1/2015)... June 1, 2015 – Atlanta, GA ... the areas of hospital medicine, emergency medicine, and pediatric ... expanded upon its partnership with AgileMD to provide the ... in a mobile application format available on iPhones, ... are very excited about the June 1 launch of ...
(Date:6/1/2015)... InstantLabs will co-develop and commercialize a ... a Cooperative Research and Development Agreement (CRADA) with the ... with U.S. Farm Bill legislation, only members of the ... the United States. , InstantLabs’ DNA-based technology will ... need rather than requiring samples be sent to centralized ...
Breaking Medicine News(10 mins):Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 3Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 4Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 2Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 3Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 4
... Human papillomavirus infection linked to better prognosis, research suggests ... the human papillomavirus (HPV) may improve survival in patients ... They said the finding may explain why black Americans, ... poorer head and neck cancer survival rates. , "There ...
... , , Association,s Anti-Fraud ... Fraud, and Abuse in Medicare , , ... strongly supports the recent Medicare Fraud Strike Force crackdown on Medicare ... takes vital resources away from seniors and patients. Reducing fraud and ...
... , YOUNTVILLE, Calif., July 30 The following is being ... WHAT: A special hearing of the California Senate Veterans Affairs Committee at the ... was originally , scheduled for Friday, July 31, 2009 at 9 a.m.. , ... , ...
... , , DETROIT, July 30 ... Rev. Dr. Wendell Anthony: , , Congressman Thaddeus ... to apologize for his remarks to the Cambridge Police Department. ... he should start by issuing an apology to the citizens of ...
... PASADENA, Calif., July 30 AutoImmune Inc. (OTC ... Corp., and Eli Lilly and Company reported that dirucotide ... progression, as measured by the Expanded Disability Status Scale ... with secondary progressive multiple sclerosis (SPMS). In addition, there ...
... PLEASANTON, Calif., July 30 Thoratec Corporation (Nasdaq: THOR ... save, support and restore failing hearts, today announced that it will ... months of fiscal 2009 on Wednesday, August 5. , , ... its financial results and operating activities open to all interested parties ...
Cached Medicine News:Health News:Virus May Affect Survival in Head and Neck Cancer 2Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 2Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 3Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 4Health News:Clinical Trial by Licensee Does Not Meet Primary Endpoint 2Health News:Thoratec Schedules Second Quarter Conference Call, Webcast 2
Inquire...
... System consists of a sterile Hemostatic ... Compression System.,Both devices work together to ... achieves topical hemostasis by facilitating clotting ... Femoral Compression System provides external compression ...
... PRAXIS is an Electronic Medical Record system. ... EKG's, Vital Statistics, Medications, and everything you would ... charts cost you money. Someone has to write ... them, and organize them. Paper Charts get lost. ...
... Bausch & Lomb's Orbscan IIz is ... elevates diagnostics beyond mere topography. Unlike current ... the eye at standard points, the Orbscan ... 1.5 seconds to meticulously map the entire ...
Medicine Products: